Wordt geladen...

Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations

LESSONS LEARNED. This single‐arm, phase II study shows that concurrent EGFR‐tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non‐small cell lung cancer harboring EGFR active mutations provides long‐term control for the primary lung lesion, and 1‐year prog...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Zheng, LinPeng, Wang, Yanmei, Xu, Zihan, Yang, Qiao, Zhu, Guangkuo, Liao, Xing‐Yun, Chen, Xiewan, Zhu, Bo, Duan, Yuzhong, Sun, Jianguo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2019
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693693/
https://ncbi.nlm.nih.gov/pubmed/31040256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0285
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!